Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Smoking and Parkinson disease: Evidence for gene-by-smoking interactions.

Lee PC, Ahmed I, Loriot MA, Mulot C, Paul KC, Bronstein JM, Ritz B, Elbaz A.

Neurology. 2018 Feb 13;90(7):e583-e592. doi: 10.1212/WNL.0000000000004953. Epub 2018 Jan 19.

PMID:
29352099
2.

Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease.

Paul KC, Schulz J, Bronstein JM, Lill CM, Ritz BR.

JAMA Neurol. 2018 Jan 16. doi: 10.1001/jamaneurol.2017.4206. [Epub ahead of print]

PMID:
29340614
3.

Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.

Kusters CDJ, Paul KC, Guella I, Bronstein JM, Sinsheimer JS, Farrer MJ, Ritz BR.

Parkinsonism Relat Disord. 2018 Feb;47:39-44. doi: 10.1016/j.parkreldis.2017.11.339. Epub 2017 Nov 24.

PMID:
29191473
4.

Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.

Weiss KH, Askari FK, Czlonkowska A, Ferenci P, Bronstein JM, Bega D, Ala A, Nicholl D, Flint S, Olsson L, Plitz T, Bjartmar C, Schilsky ML.

Lancet Gastroenterol Hepatol. 2017 Dec;2(12):869-876. doi: 10.1016/S2468-1253(17)30293-5. Epub 2017 Oct 5.

PMID:
28988934
5.

Parkinson's disease is associated with DNA methylation levels in human blood and saliva.

Chuang YH, Paul KC, Bronstein JM, Bordelon Y, Horvath S, Ritz B.

Genome Med. 2017 Aug 30;9(1):76. doi: 10.1186/s13073-017-0466-5.

6.

Occupational pesticide use and Parkinson's disease in the Parkinson Environment Gene (PEG) study.

Narayan S, Liew Z, Bronstein JM, Ritz B.

Environ Int. 2017 Oct;107:266-273. doi: 10.1016/j.envint.2017.04.010. Epub 2017 Aug 2.

PMID:
28779877
7.

Organophosphate pesticides and PON1 L55M in Parkinson's disease progression.

Paul KC, Sinsheimer JS, Cockburn M, Bronstein JM, Bordelon Y, Ritz B.

Environ Int. 2017 Oct;107:75-81. doi: 10.1016/j.envint.2017.06.018. Epub 2017 Jul 6.

PMID:
28689109
8.

Neuropsychological outcomes from deep brain stimulation-stimulation versus micro-lesion.

Pham T, Bronstein JM.

Ann Transl Med. 2017 May;5(10):217. doi: 10.21037/atm.2017.02.16. No abstract available.

9.

Editor's Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinson's Disease Risk.

Sanders LH, Paul KC, Howlett EH, Lawal H, Boppana S, Bronstein JM, Ritz B, Greenamyre JT.

Toxicol Sci. 2017 Jul 1;158(1):188-198. doi: 10.1093/toxsci/kfx086.

PMID:
28460087
10.

Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos.

Lulla A, Barnhill L, Bitan G, Ivanova MI, Nguyen B, O'Donnell K, Stahl MC, Yamashiro C, Klärner FG, Schrader T, Sagasti A, Bronstein JM.

Environ Health Perspect. 2016 Nov;124(11):1766-1775. Epub 2016 Jun 15.

11.

Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease.

Gatto NM, Paul KC, Sinsheimer JS, Bronstein JM, Bordelon Y, Rausch R, Ritz B.

J Neurol Sci. 2016 Nov 15;370:100-106. doi: 10.1016/j.jns.2016.09.013. Epub 2016 Sep 11.

12.

Writeclick: Neuropsychological outcome after deep brain stimulation for Parkinson disease.

Massano J, Bronstein JM.

Neurology. 2016 Apr 19;86(16):1563-4. doi: 10.1212/01.wnl.0000482821.31709.31. No abstract available.

PMID:
27164452
13.

APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Paul KC, Rausch R, Creek MM, Sinsheimer JS, Bronstein JM, Bordelon Y, Ritz B.

J Parkinsons Dis. 2016 Apr 2;6(2):349-59. doi: 10.3233/JPD-150762.

PMID:
27061069
14.

Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease.

Ritz BR, Paul KC, Bronstein JM.

Curr Environ Health Rep. 2016 Mar;3(1):40-52. doi: 10.1007/s40572-016-0083-2. Review.

PMID:
26857251
15.

Neuropsychological outcome after deep brain stimulation for Parkinson disease.

Bronstein JM.

Neurology. 2015 Oct 20;85(16):1433. doi: 10.1212/01.wnl.0000473050.23344.3c. No abstract available.

PMID:
26481931
16.

Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease.

Narayan S, Sinsheimer JS, Paul KC, Liew Z, Cockburn M, Bronstein JM, Ritz B.

Environ Res. 2015 Nov;143(Pt A):98-106. doi: 10.1016/j.envres.2015.08.022. Epub 2015 Oct 19.

17.

Fetal Mortality in the Delta.

Sandlin AT, Bronstein JM, Rabie NZ, Wendel PJ, Hughes DS, Magann EF.

South Med J. 2015 Jul;108(7):389-92. doi: 10.14423/SMJ.0000000000000305.

PMID:
26192933
18.

Initial Impacts of the Patient Care Networks of Alabama Initiative.

Bronstein JM, Morrisey MA, Sen B, Engler S, Smith WK.

Health Serv Res. 2016 Feb;51(1):146-66. doi: 10.1111/1475-6773.12319. Epub 2015 Jun 9.

19.

Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease.

Bronstein JM, Paul K, Yang L, Haas RH, Shults CW, Le T, Ritz B.

Mov Disord. 2015 May;30(6):862-6. doi: 10.1002/mds.26164. Epub 2015 Mar 11.

20.

Author response.

Bronstein JM, Fitzmaurice A.

Neurology. 2014 Nov 11;83(20):1879-80. No abstract available.

PMID:
25544982
21.

Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease.

Burke WJ, Bronstein JM, Fitzmaurice A.

Neurology. 2014 Nov 11;83(20):1879-80. doi: 10.1212/01.wnl.0000457072.94144.8f. No abstract available.

PMID:
25385831
22.

The rationale driving the evolution of deep brain stimulation to constant-current devices.

Bronstein JM, Tagliati M, McIntyre C, Chen R, Cheung T, Hargreaves EL, Israel Z, Moffitt M, Montgomery EB, Stypulkowski P, Shils J, Denison T, Vitek J, Volkman J, Wertheimer J, Okun MS.

Neuromodulation. 2015 Feb;18(2):85-8; discussion 88-9. doi: 10.1111/ner.12227. Epub 2014 Aug 29.

PMID:
25171762
23.

Pesticides and Parkinson's disease: is it in your genes?

Barnhill LM, Bronstein JM.

Neurodegener Dis Manag. 2014;4(3):197-200. doi: 10.2217/nmt.14.18. No abstract available.

24.

Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity.

O'Donnell KC, Lulla A, Stahl MC, Wheat ND, Bronstein JM, Sagasti A.

Dis Model Mech. 2014 May;7(5):571-82. doi: 10.1242/dmm.013185. Epub 2014 Mar 13.

25.

Distributing medical expertise: the evolution and impact of telemedicine in arkansas.

Lowery CL, Bronstein JM, Benton TL, Fletcher DA.

Health Aff (Millwood). 2014 Feb;33(2):235-43. doi: 10.1377/hlthaff.2013.1001. Review. Erratum in: Health Aff (Millwood). 2015 Jan;34(1):189.

PMID:
24493766
26.

Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease.

Fitzmaurice AG, Rhodes SL, Cockburn M, Ritz B, Bronstein JM.

Neurology. 2014 Feb 4;82(5):419-26. doi: 10.1212/WNL.0000000000000083. Erratum in: Neurology. 2014 Nov 11;83(20):1880.

27.

The association between ambient exposure to organophosphates and Parkinson's disease risk.

Wang A, Cockburn M, Ly TT, Bronstein JM, Ritz B.

Occup Environ Med. 2014 Apr;71(4):275-81. doi: 10.1136/oemed-2013-101394. Epub 2014 Jan 16.

28.

Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.

Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Loriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B.

Neurobiol Dis. 2014 Feb;62:172-8. doi: 10.1016/j.nbd.2013.09.019. Epub 2013 Oct 8.

29.

Household organophosphorus pesticide use and Parkinson's disease.

Narayan S, Liew Z, Paul K, Lee PC, Sinsheimer JS, Bronstein JM, Ritz B.

Int J Epidemiol. 2013 Oct;42(5):1476-85. doi: 10.1093/ije/dyt170. Epub 2013 Sep 20.

30.

Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease.

Rhodes SL, Fitzmaurice AG, Cockburn M, Bronstein JM, Sinsheimer JS, Ritz B.

Environ Res. 2013 Oct;126:1-8. doi: 10.1016/j.envres.2013.08.001. Epub 2013 Aug 27.

31.

Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.

Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O'Donnell KC, Barnhill L, Casida JE, Cockburn M, Sagasti A, Stahl MC, Maidment NT, Ritz B, Bronstein JM.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):636-41. doi: 10.1073/pnas.1220399110. Epub 2012 Dec 24.

32.

Use of specialty OB consults during high-risk pregnancies in a Medicaid-covered population: initial impact of the Arkansas ANGELS intervention.

Bronstein JM, Ounpraseuth S, Jonkman J, Fletcher D, Nugent RR, McGhee J, Lowery CL.

Med Care Res Rev. 2012 Dec;69(6):699-720. doi: 10.1177/1077558712458157. Epub 2012 Sep 4.

PMID:
22951314
33.

Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety.

Pouratian N, Thakkar S, Kim W, Bronstein JM.

Degener Neurol Neuromuscul Dis. 2012 Sep 4;2012(2). doi: 10.2147/DNND.S25750.

34.

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group.

Neurology. 2012 Jul 3;79(1):55-65. doi: 10.1212/WNL.0b013e31825dcdc1. Epub 2012 Jun 20.

35.

A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.

Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klärner FG, Schrader T, Stahl M, Bitan G, Bronstein JM.

Neurotherapeutics. 2012 Apr;9(2):464-76. doi: 10.1007/s13311-012-0105-1. Erratum in: Neurotherapeutics. 2012 Apr;9(2):486. Lakshmanan, Ravi [corrected to Lakshmanan, Rajeswari].

36.

Improving perinatal regionalization for preterm deliveries in a Medicaid covered population: initial impact of the Arkansas ANGELS intervention.

Bronstein JM, Ounpraseuth S, Jonkman J, Lowery CL, Fletcher D, Nugent RR, Hall RW.

Health Serv Res. 2011 Aug;46(4):1082-103. doi: 10.1111/j.1475-6773.2011.01249.x. Epub 2011 Mar 17.

37.

Providing general and preconception health care to low income women in family planning settings: perception of providers and clients.

Bronstein JM, Felix HC, Bursac Z, Stewart MK, Foushee HR, Klapow J.

Matern Child Health J. 2012 Feb;16(2):346-54. doi: 10.1007/s10995-011-0744-6.

PMID:
21258961
38.

The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.

Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, Taylor JS, Cole JA, Zimran A, Weinreb NJ.

Blood Cells Mol Dis. 2011 Jan 15;46(1):95-102. doi: 10.1016/j.bcmd.2010.10.006. Epub 2010 Nov 10.

39.

Replication of GWAS associations for GAK and MAPT in Parkinson's disease.

Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B.

Ann Hum Genet. 2011 Mar;75(2):195-200. doi: 10.1111/j.1469-1809.2010.00616.x. Epub 2010 Nov 8.

40.

Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues.

Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR.

Arch Neurol. 2011 Feb;68(2):165. doi: 10.1001/archneurol.2010.260. Epub 2010 Oct 11. Review.

41.

Late preterm infants: birth outcomes and health care utilization in the first year.

Bird TM, Bronstein JM, Hall RW, Lowery CL, Nugent R, Mays GP.

Pediatrics. 2010 Aug;126(2):e311-9. doi: 10.1542/peds.2009-2869. Epub 2010 Jul 5.

PMID:
20603259
42.

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group.

N Engl J Med. 2010 Jun 3;362(22):2077-91. doi: 10.1056/NEJMoa0907083.

43.

Mechanisms of rotenone-induced proteasome inhibition.

Chou AP, Li S, Fitzmaurice AG, Bronstein JM.

Neurotoxicology. 2010 Aug;31(4):367-72. doi: 10.1016/j.neuro.2010.04.006. Epub 2010 Apr 22.

44.

Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease.

Manthripragada AD, Costello S, Cockburn MG, Bronstein JM, Ritz B.

Epidemiology. 2010 Jan;21(1):87-94. doi: 10.1097/EDE.0b013e3181c15ec6.

45.

Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset.

Plaitakis A, Latsoudis H, Kanavouras K, Ritz B, Bronstein JM, Skoula I, Mastorodemos V, Papapetropoulos S, Borompokas N, Zaganas I, Xiromerisiou G, Hadjigeorgiou GM, Spanaki C.

Eur J Hum Genet. 2010 Mar;18(3):336-41. doi: 10.1038/ejhg.2009.179. Epub 2009 Oct 14.

46.

Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.

Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Mortazavi F, Chesselet MF, Bronstein JM.

J Biol Chem. 2008 Dec 12;283(50):34696-703. doi: 10.1074/jbc.M802210200. Epub 2008 Sep 25.

47.

Policy levers that improve low income children's access to mental health services.

Bronstein JM.

Med Care. 2008 Jun;46(6):555-7. doi: 10.1097/MLR.0b013e31817afd04. No abstract available.

PMID:
18520308
48.

Issues and biases in matching medicaid pregnancy episodes to vital records data: the Arkansas experience.

Bronstein JM, Lomatsch CT, Fletcher D, Wooten T, Lin TM, Nugent R, Lowery CL.

Matern Child Health J. 2009 Mar;13(2):250-9. doi: 10.1007/s10995-008-0347-z. Epub 2008 May 1.

PMID:
18449631
49.

Statin use and the risk of Parkinson disease.

Wahner AD, Bronstein JM, Bordelon YM, Ritz B.

Neurology. 2008 Apr 15;70(16 Pt 2):1418-22. doi: 10.1212/01.wnl.0000286942.14552.51. Epub 2008 Jan 9.

50.

Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease.

Wahner AD, Bronstein JM, Bordelon YM, Ritz B.

Neurology. 2007 Nov 6;69(19):1836-42.

PMID:
17984451

Supplemental Content

Loading ...
Support Center